Autolus Therapeutics (AUTL) Interest Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Interest Expenses for 9 consecutive years, with $22.8 million the latest figure, recorded in Q4 2025.

• Quarterly Interest Expenses rose 174.06% year-over-year to $22.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.9 million (up 38.38% YoY) and the FY2025 annual result came in at $248.0 million, up 57.98% from the prior year.
• Interest Expenses retreated to $22.8 million in Q4 2025 per AUTL's latest filing, from $118.7 million in the prior quarter.
• Over the last five years, Interest Expenses for AUTL reached as high as $119.8 million in Q2 2025 and fell as low as -$30.8 million in Q4 2024.
• A 5-year average of $24.3 million and a median of $5.0 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2021 — Interest Expenses soared 1205.0% — and 2024, when it tumbled 202.35%.
• Year by year, Interest Expenses stood at $1.1 million in 2021, then soared by 212.85% to $3.5 million in 2022, then jumped by 771.51% to $30.1 million in 2023, then slumped by 202.35% to -$30.8 million in 2024, then jumped by 174.06% to $22.8 million in 2025.
• According to Business Quant data, Interest Expenses over the past three periods registered $22.8 million, $118.7 million, and $119.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.